Recap - As expected, Trillium Therapeutics (SCTPF)(TR.TO) announced this week an upcoming reverse-split, NASDAQ uplisting, and reiterated the timeline for bringing its SIRPaFc antibody-like fusion proteins into the clinic … Continue Reading
Read nowInsights - Dendreon (DNDN) has filed for bankruptcy protection and reached agreement with a majority of its debtholders to convert to equity in the company.
Read nowRecap - This week was jam-packed with market-moving events in biotech, punctuated on Thursday afternoon with an accounting scandal of epic proportions at Salix Pharmaceuticals (SLXP), which makes up … Continue Reading
Read nowInsights - At $14.5 million, global sales of Ariad Pharmaceuticals’ (ARIA) Iclusig (ponatinib) came in below consensus expectations for $16 million in the quarter. Though sales are up … Continue Reading
Read nowRecap - Despite this asset class having just entered human testing, there’s significant excitement surrounding the therapeutic potential of blocking CD47 and the “DO NOT EAT” signal … Continue Reading
Read nowRecap - What a week. The iShares NASDAQ Biotechnology (IBB) made new all-time highs and is drastically outpacing the S&P 500, as well as the NASDAQ composite, for the … Continue Reading
Read nowInsights - Shire PLC (SHPG) reported record third quarter revenues on Friday – $1.6 billion and 33% growth over the year-ago quarter – with earnings of $2.93 per share. The company … Continue Reading
Read now
